Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The company emphasised that improving access to effective therapies is therefore an important component of addressing the nations health challenge (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online
The SELECT trial demonstrated cardiovascular benefits of semaglutide independent of weight loss, leading to a cardiovascular risk reduction indication that does not require a specific BMI
Saxenda (liraglutide) Its an older daily injectable GLP-1 approved for weight management
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, structurally modified from native GLP-1 with a fatty-acid side chain that enables reversible albumin binding extending its half-life to approximately one week and enabling once-weekly dosing regimens studied extensively in clinical trials
GLP-1 treatment is safe and effective and can help stimulate weight loss in those who are overweight or medically obese
The remaining 20-30% may experience lingering symptoms into weeks three and four
US$ 26.68
US$ 24.18
US$ 20.47
US$ 22.07
